MGX
NASDAQMetagenomi Therapeutics Inc.
$1.50+0.05 (+3.81%)
News25/Ratings8
Price$1.50+0.07 (+4.90%)
01:30 PM07:45 PM
News · 26 weeks28-83%
2025-11-022026-04-26
Mix1290d
- Insider6(50%)
- Other3(25%)
- SEC Filings3(25%)
Latest news
25 items- PRMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing EfficiencyEMERYVILLE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced a publication in Nature Structural & Molecular Biology highlighting the discovery and detailed characterization of MG119-28, a compact CRISPR nuclease with superior editing efficiency relative to previously identified compact nucleases. The publication, titled "Comparative characterization of Cas12f orthologs reveals mechanistic features underlying enhanced genome editing efficiency" highlights the potential of MG119-28 (formally na
- INSIDERSEC Form 4 filed by Irish Jian4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERSEC Form 4 filed by Wein Matthew4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERSEC Form 4 filed by Wapnick Pamela4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERChief Financial Officer Wapnick Pamela sold $2,530 worth of shares (1,581 units at $1.60), decreasing direct ownership by 0.84% to 187,375 units (SEC Form 4)4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDEROfficer Wein Matthew sold $771 worth of shares (482 units at $1.60), decreasing direct ownership by 0.42% to 114,549 units (SEC Form 4)4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERChief Executive Officer Irish Jian gifted 228,462 shares and sold $2,571 worth of shares (1,607 units at $1.60), decreasing direct ownership by 41% to 333,770 units (SEC Form 4)4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- SECSEC Form S-8 filed by Metagenomi Therapeutics Inc.S-8 - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- SECSEC Form 10-K filed by Metagenomi Therapeutics Inc.10-K - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- SECMetagenomi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- PRMetagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial ResultsCompleted pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application ("IND") in 4Q 2026 Announced corporate name change to Metagenomi Therapeutics, Inc. to reflect Company's strategic evolution $160.8 million in cash, cash equivalents and available-for-sale marketable securities as of December 31, 2025 with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on it
- PRMetagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare ConferenceEMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the 46th Annual TD Cowen Healthcare Conference, being held in Boston, MA, on Monday, March 2, 2026 at 11:10 a.m. ET. The fireside chat presentation will be made available on the "News & Events" page in the Investors section of the Company's website at https://ir.metagenomi.co/news-events/events. About Metageno
- SECMetagenomi Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Metagenomi, Inc. (0001785279) (Filer)
- PRMetagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate OutlookNew name reflects the Company's strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs); MGX-001 on track for IND/CTA submissions in 4Q 2026 Cash runway anticipated through 4Q 2027 EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that it has completed its corporate name change
- INSIDERDirector Thomas Brian C. sold $6,786 worth of shares (3,830 units at $1.77), decreasing direct ownership by 0.15% to 2,510,960 units (SEC Form 4)4 - Metagenomi, Inc. (0001785279) (Issuer)
- INSIDEROfficer Wein Matthew sold $353 worth of shares (199 units at $1.77), decreasing direct ownership by 0.17% to 115,031 units (SEC Form 4)4 - Metagenomi, Inc. (0001785279) (Issuer)
- INSIDERChief Financial Officer Wapnick Pamela sold $2,793 worth of shares (1,576 units at $1.77), decreasing direct ownership by 0.83% to 188,956 units (SEC Form 4)4 - Metagenomi, Inc. (0001785279) (Issuer)
- INSIDERChief Executive Officer Irish Jian sold $2,839 worth of shares (1,602 units at $1.77), decreasing direct ownership by 0.28% to 563,839 units (SEC Form 4)4 - Metagenomi, Inc. (0001785279) (Issuer)
- INSIDERDirector Thomas Brian C. sold $4,889 worth of shares (2,701 units at $1.81), decreasing direct ownership by 0.11% to 2,514,790 units (SEC Form 4)4 - Metagenomi, Inc. (0001785279) (Issuer)
- INSIDERChief Financial Officer Wapnick Pamela sold $2,853 worth of shares (1,576 units at $1.81) and was granted 120,000 shares, increasing direct ownership by 164% to 190,532 units (SEC Form 4)4 - Metagenomi, Inc. (0001785279) (Issuer)
- INSIDERChief Executive Officer Irish Jian sold $2,900 worth of shares (1,602 units at $1.81) and was granted 248,500 shares, increasing direct ownership by 78% to 565,441 units (SEC Form 4)4 - Metagenomi, Inc. (0001785279) (Issuer)
- INSIDEROfficer Wein Matthew sold $360 worth of shares (199 units at $1.81) and was granted 96,000 shares, increasing direct ownership by 493% to 115,230 units (SEC Form 4)4 - Metagenomi, Inc. (0001785279) (Issuer)
- PRMetagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature ConferenceEMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that the Company will present new preclinical data supporting the third target, APOC3, in its collaboration with Ionis Pharmaceuticals at the Nature Conference "Cracking the Code: Nucleic Acid Medicines Coming of Age" taking place December 8-10, 2025, in Boston, MA. Nature Conference "Cracking the Code: Nucleic Acid Medicines Coming of Age" Title: CRISPR/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia Present
- PRMetagenomi to Present at Jefferies Global Healthcare Conference in LondonEMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A, President and Chief Executive Officer of Metagenomi, will be presenting at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025, at 9:30 a.m. GMT. A live webcast will be available in the investor section of the company's website at https://ir.metagenomi.co/ and a replay will be available for a limited time at the same address. About Metagenomi Metagenomi is an in vivo genome editing
- SECSEC Form 10-Q filed by Metagenomi Inc.10-Q - Metagenomi, Inc. (0001785279) (Filer)